Utilization of Gonadotropin-Releasing Hormone Antagonist in Uterine Adenomyosis Particularly on Association with Fibroids & Infertility - Offers Some Hope for Saving Uterus & Future Fertility - A Short Communication

arlier we had reviewed the detailed etiopathogenesis, treatment of uterine adenomyosis inclusive of how its origination takes place. Additionally, we have detailed mechanistic modes by which GnRH analogues work on adenomyosis. There exist variable hormonal along with non-hormonal therapies that have been prescribed for symptomatic relief, inclusive of nonsteroidal anti-inflammatory drugs, combined estrogen–progestin possessing contraceptives, as well as systemic in addition to intrauterine progestins, inclusive of 52 mg levonorgestrel-releasing intrauterine devices, along with gonadotropin-releasing hormone (GnRH) agonists as well antagonists. Despite that, all GnRH analogues inclusive of 300 mg of elagolix twice daily with add-back therapy (1 mg of estradiol/0.5 mg of norethindrone acetate once a day) significantly abridged HMB in women with uterine fibroids along with concurrent adenomyosis, pointing that elagolix efficaciousness was not inimicaly impacted by the existence of adenomyosis. However, that rapid recurrence of symptoms is canonically found subsequent to culmination of therapy. Results from the aforementioned study corroborated, that linzagolix delivered at a greater dose for 12 weeks, with subsequent lesser maintenance dose for a further 12 weeks, is a viable alternative for treatment of adenomyosis- associated symptoms .